Indeed, CNA burden has been previously shown to be a strong predictor of recurrence and survival in prostate cancer (68,69) implicating methylation of GSTM2 and GSTP1 in the prognosis of prostate cancer patients via allowing for higher amount of genomic aberrations. The gene discussed is GSTM2; the disease is prostate carcinoma.